FRACP

egnite, Inc. Unveils Research on Mitral Regurgitation at Transcatheter Cardiovascular Therapeutics Conference 2023

Retrieved on: 
Thursday, October 26, 2023

egnite, Inc. , a leading cardiovascular digital health company, announced today that novel research on mitral regurgitation (MR) was presented by cardiologist Rahul Sharma, MBBS, FRACP, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

Key Points: 
  • egnite, Inc. , a leading cardiovascular digital health company, announced today that novel research on mitral regurgitation (MR) was presented by cardiologist Rahul Sharma, MBBS, FRACP, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
  • These findings unveiled critical insights into treatment patterns and associated outcomes in patients with MR.
  • The implications of delayed treatment, particularly in moderate-to-severe MR, cannot be overstated, as it may lead to poor patient outcomes."
  • This research represents one of the largest real-world analyses of treatment patterns and associated outcomes for patients with MR and highlights the importance of timely intervention.

Insulet to Present Extended Real-World Evidence and Best Practices for Optimizing Care with Omnipod® 5

Retrieved on: 
Monday, October 2, 2023

The Company will present extended real-world evidence (RWE) of improved outcomes and optimization of care using the Omnipod 5 Automated Insulin Delivery System, one full year after the commercial launch of Omnipod 5 in the United States.

Key Points: 
  • The Company will present extended real-world evidence (RWE) of improved outcomes and optimization of care using the Omnipod 5 Automated Insulin Delivery System, one full year after the commercial launch of Omnipod 5 in the United States.
  • There are four oral presentations at the EASD program, covering Omnipod 5 and the Omnipod DASH® Insulin Management System.
  • Dr. Lalantha Leelarathna, a diabetes specialist from the U.K., will Chair the session and present extended Omnipod 5 RWE and care strategies for optimizing glycemic outcomes, with Jade Byrne sharing her experience using the system.
  • Insulet will continue to provide updates on future European launches expected to occur in France, Italy, Sweden, Denmark, Norway, and Finland.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD

Retrieved on: 
Monday, October 2, 2023

Regardless of insulin delivery method, multiple daily injections or insulin pump therapy, real-time CGM has greater and statistically significant HbA1c reduction when compared to self-monitoring blood glucose over seven years.

Key Points: 
  • Regardless of insulin delivery method, multiple daily injections or insulin pump therapy, real-time CGM has greater and statistically significant HbA1c reduction when compared to self-monitoring blood glucose over seven years.
  • This news follows the recent launch of the Omnipod 5 Automated Insulin Delivery System connected to Dexcom G6 in the UK and Germany.
  • “Championing access to real-time CGM technology for people with all types of diabetes is central to our mission at Dexcom,” said Alex Moussa, senior vice president and general manager of EMEA & LATAM at Dexcom.
  • “With Dexcom G7, Dexcom G6 and Dexcom ONE, we have the most complete portfolio of CGM systems for people with all types of diabetes and we continue to work on expanding access to our life-changing technology.

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

Retrieved on: 
Thursday, September 14, 2023

Helen (Honey) Heussler, MBBS FRACP, DM, Associate Professor, Faculty of Medicine, Child Health Research Centre, University of Queensland, Australia, will present data from the open-label Phase 2 INSPIRE trial.

Key Points: 
  • Helen (Honey) Heussler, MBBS FRACP, DM, Associate Professor, Faculty of Medicine, Child Health Research Centre, University of Queensland, Australia, will present data from the open-label Phase 2 INSPIRE trial.
  • A copy of the presentation will be available on the Zynerba corporate website at www.zynerba.com/publications .
  • Zygel was shown to be generally well tolerated, and the safety profile was consistent with previously released data from other Zygel clinical trials.
  • Three patients reported treatment related adverse events which were all mild in severity and application site related.

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Retrieved on: 
Wednesday, September 13, 2023

Details are as follows:

Key Points: 
  • Details are as follows:
    To register for the event, click here .
  • The Vaccitech management team will provide a clinical overview of VTP-300, the first antigen-specific immunotherapy that has been shown to induce sustained reductions in Hepatitis B surface antigen, a marker of the disease.
  • Vaccitech is studying VTP-300, including in combination with siRNA and low-dose anti-PD-1 antibodies, as part of the search for a regimen that could lead to a potential functional cure for HBV.
  • A live Q&A session will follow the formal presentations.

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System in Germany

Retrieved on: 
Monday, August 28, 2023

The system1 includes the tubeless Pod enhanced with SmartAdjust™ technology and a handheld Controller integrated with the SmartBolus Calculator.

Key Points: 
  • The system1 includes the tubeless Pod enhanced with SmartAdjust™ technology and a handheld Controller integrated with the SmartBolus Calculator.
  • The system is interoperable with Dexcom G6 for automated insulin delivery to help protect against high and low glucose levels 2.
  • “Being tubeless makes my life so much easier, and the addition of an automated insulin delivery system will give me even more freedom to manage my type 1 diabetes.
  • 1Integration with the Dexcom G6 CGM system is required for automated insulin delivery.

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Retrieved on: 
Friday, July 28, 2023

SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody.

Key Points: 
  • SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody.
  • “Initiation of the phase 3 BEYOND study is an important step towards our goal of providing an innovative treatment option for patients with IgAN, a disease with high unmet need and limited treatment options,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics.
  • “IgAN is the most common primary glomerular disease worldwide with limited treatment options currently available, causing many patients to progress to end-stage kidney disease, requiring dialysis or kidney transplant.
  • With the potential to be disease-modifying based on the encouraging results observed in the phase 1/2 study, I believe zigakibart could be an important new therapeutic treatment option for patients with IgAN.”

LinKinVax Introduces its Scientific Advisory Board with the Appointment of Three Leading Experts in Immunology and Epidemiology

Retrieved on: 
Wednesday, April 26, 2023

LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.

Key Points: 
  • LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.
  • “We are delighted to welcome Prof. Anna Giuliano, Prof. Sharon Lewin and Prof. Giuseppe Pantaleo to our Scientific Advisory Board.
  • “We are very pleased to have convinced these leading experts to join our scientific committee.
  • Their skills and experience in immunology and epidemiology will help guide and optimise all aspects of our clinical development plans for our DC-targeting vaccine platform.

Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

Retrieved on: 
Tuesday, April 18, 2023

BASKING RIDGE, N.J. and SUBIACO, Australia, April 18, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and WARPNINE Incorporated (“WARPNINE”), Western Australia’s first not-for-profit clinical research organization for pancreatic, gastro-intestinal and rare cancers, today announced the treatment of the first patient in the iLSTA Trial of Lisata’s LSTA1 in combination with standard-of-care chemotherapy and immunotherapy as a first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma (“PDAC”).

Key Points: 
  • As the study sponsor, WARPNINE will provide all funding and manage all recruitment activities for the study while Lisata will provide the study drug, LSTA1, as well as regulatory support.
  • WARPNINE and Lisata will share use of the data with the goal of advancing development of LSTA1 toward registration to the benefit of patients in need.
  • The extraordinary support of the WARPNINE community has enabled us to sponsor this innovative and potentially game-changing trial.
  • “We are thrilled by the progress being made to help advance LSTA1 through the clinical trial process and are grateful to WARPNINE for their financial and operational support.”

SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023

The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida.

Key Points: 
  • The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida.
  • “The lifirafenib plus mirdametinib combination represents a novel targeted approach to treat solid tumors driven by RAS/RAF mutations, and other MAPK pathway aberrations.
  • As of the data cut-off of January 20, 2023, 71 patients were treated across 9 dose levels evaluating different dosing regimens.
  • Of the 4 endometrial cancer patients treated, 2 (50%) had objective responses in tumors that harbor BRAF fusion mutation or KRAS mutation, respectively.